Loading…
Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents
Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. Preliminary structure activity relationsh...
Saved in:
Published in: | European journal of medicinal chemistry 2015-12, Vol.106, p.144-156 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c428t-8e0413af105bb9b7604608d039c7b689252a5d65bffe3fef4febb9298b967fbb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c428t-8e0413af105bb9b7604608d039c7b689252a5d65bffe3fef4febb9298b967fbb3 |
container_end_page | 156 |
container_issue | |
container_start_page | 144 |
container_title | European journal of medicinal chemistry |
container_volume | 106 |
creator | Ng, Pearly Shuyi Manjunatha, Ujjini H. Rao, Srinivasa P.S. Camacho, Luis R. Ma, Ngai Ling Herve, Maxime Noble, Christian G. Goh, Anne Peukert, Stefan Diagana, Thierry T. Smith, Paul W. Kondreddi, Ravinder Reddy |
description | Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. Preliminary structure activity relationship on the isobutyl group with higher cycloalkyl groups at 6-position of pyridone ring has enabled us to significant improvement of potency against Mtb. The lead compound 30j, a dimethylcyclohexyl group on the 6-position of the pyridone, displayed desirable in vitro potency against both drug sensitive and multi-drug resistant TB clinical isolates. In addition, 30j displayed favorable oral pharmacokinetic properties and demonstrated in vivo efficacy in mouse model. These results emphasize the importance of 4-hydroxy-2-pyridones as a new chemotype and further optimization of properties to treat MDR-TB.
[Display omitted]
•Hit pyridone 1 inhibited growth of Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis.•SAR on 6-position of pyridone 1 significantly improved potency and lead compound 30j displayed 50 nM activity against Mtb.•Lead 30j showed favorable oral PK and demonstrated in vivo efficacy in mouse model.•Mechanism of action studies indicated thatpyridones are direct inhibitors of InhA. |
doi_str_mv | 10.1016/j.ejmech.2015.10.008 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1733929597</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523415302890</els_id><sourcerecordid>1733929597</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-8e0413af105bb9b7604608d039c7b689252a5d65bffe3fef4febb9298b967fbb3</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVJaTZp_0EpPubizejTdg-FENokEOih7VlI8qirxWttJXmp_3292TTHnAZenneGeQj5SGFNgarr7Rq3O3SbNQMql2gN0L4hK9qotuZMijOyAsZ4LRkX5-Qi5y0ASAXwjpwzJYVQrFsR96OkyZUpYWVcCYdQ5irhYEqIY96Efa6ir0S9mfsU_841q_dzCn0cMX-ubqoxHnCo3GDyE2fGEspkMblpiDnkyvzGseT35K03Q8YPz_OS_Pr29eftff34_e7h9uaxdoK1pW4RBOXGU5DWdrZRIBS0PfDONVa1HZPMyF5J6z1yj154XDjWtbZTjbeWX5Kr0959in8mzEXvQnY4DGbEOGVNG84XXnbNgooT6lLMOaHX-xR2Js2agj7q1Vt90quPeo_ponepfXq-MNkd9i-l_z4X4MsJwOXPQ8Cksws4OuxDQld0H8PrF_4BHh2PHQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1733929597</pqid></control><display><type>article</type><title>Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents</title><source>ScienceDirect Freedom Collection</source><creator>Ng, Pearly Shuyi ; Manjunatha, Ujjini H. ; Rao, Srinivasa P.S. ; Camacho, Luis R. ; Ma, Ngai Ling ; Herve, Maxime ; Noble, Christian G. ; Goh, Anne ; Peukert, Stefan ; Diagana, Thierry T. ; Smith, Paul W. ; Kondreddi, Ravinder Reddy</creator><creatorcontrib>Ng, Pearly Shuyi ; Manjunatha, Ujjini H. ; Rao, Srinivasa P.S. ; Camacho, Luis R. ; Ma, Ngai Ling ; Herve, Maxime ; Noble, Christian G. ; Goh, Anne ; Peukert, Stefan ; Diagana, Thierry T. ; Smith, Paul W. ; Kondreddi, Ravinder Reddy</creatorcontrib><description>Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. Preliminary structure activity relationship on the isobutyl group with higher cycloalkyl groups at 6-position of pyridone ring has enabled us to significant improvement of potency against Mtb. The lead compound 30j, a dimethylcyclohexyl group on the 6-position of the pyridone, displayed desirable in vitro potency against both drug sensitive and multi-drug resistant TB clinical isolates. In addition, 30j displayed favorable oral pharmacokinetic properties and demonstrated in vivo efficacy in mouse model. These results emphasize the importance of 4-hydroxy-2-pyridones as a new chemotype and further optimization of properties to treat MDR-TB.
[Display omitted]
•Hit pyridone 1 inhibited growth of Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis.•SAR on 6-position of pyridone 1 significantly improved potency and lead compound 30j displayed 50 nM activity against Mtb.•Lead 30j showed favorable oral PK and demonstrated in vivo efficacy in mouse model.•Mechanism of action studies indicated thatpyridones are direct inhibitors of InhA.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2015.10.008</identifier><identifier>PMID: 26544629</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>4-Hydroxy-2-pyridones ; Animals ; Antitubercular Agents - chemistry ; Antitubercular Agents - metabolism ; Antitubercular Agents - pharmacology ; Antituberculosis agents ; Biological Availability ; Dose-Response Relationship, Drug ; Drug Stability ; Humans ; Mice ; Microbial Sensitivity Tests ; Microsomes, Liver - chemistry ; Microsomes, Liver - metabolism ; Models, Molecular ; Molecular Structure ; Mycobacterium tuberculosis - drug effects ; Phenotypic screen ; Pyridones - chemistry ; Pyridones - metabolism ; Pyridones - pharmacology ; Rats ; Structure activity relations ; Structure-Activity Relationship ; Tuberculosis ; Tuberculosis, Multidrug-Resistant - drug therapy ; Tuberculosis, Multidrug-Resistant - microbiology</subject><ispartof>European journal of medicinal chemistry, 2015-12, Vol.106, p.144-156</ispartof><rights>2015 Elsevier Masson SAS</rights><rights>Copyright © 2015 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-8e0413af105bb9b7604608d039c7b689252a5d65bffe3fef4febb9298b967fbb3</citedby><cites>FETCH-LOGICAL-c428t-8e0413af105bb9b7604608d039c7b689252a5d65bffe3fef4febb9298b967fbb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26544629$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ng, Pearly Shuyi</creatorcontrib><creatorcontrib>Manjunatha, Ujjini H.</creatorcontrib><creatorcontrib>Rao, Srinivasa P.S.</creatorcontrib><creatorcontrib>Camacho, Luis R.</creatorcontrib><creatorcontrib>Ma, Ngai Ling</creatorcontrib><creatorcontrib>Herve, Maxime</creatorcontrib><creatorcontrib>Noble, Christian G.</creatorcontrib><creatorcontrib>Goh, Anne</creatorcontrib><creatorcontrib>Peukert, Stefan</creatorcontrib><creatorcontrib>Diagana, Thierry T.</creatorcontrib><creatorcontrib>Smith, Paul W.</creatorcontrib><creatorcontrib>Kondreddi, Ravinder Reddy</creatorcontrib><title>Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. Preliminary structure activity relationship on the isobutyl group with higher cycloalkyl groups at 6-position of pyridone ring has enabled us to significant improvement of potency against Mtb. The lead compound 30j, a dimethylcyclohexyl group on the 6-position of the pyridone, displayed desirable in vitro potency against both drug sensitive and multi-drug resistant TB clinical isolates. In addition, 30j displayed favorable oral pharmacokinetic properties and demonstrated in vivo efficacy in mouse model. These results emphasize the importance of 4-hydroxy-2-pyridones as a new chemotype and further optimization of properties to treat MDR-TB.
[Display omitted]
•Hit pyridone 1 inhibited growth of Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis.•SAR on 6-position of pyridone 1 significantly improved potency and lead compound 30j displayed 50 nM activity against Mtb.•Lead 30j showed favorable oral PK and demonstrated in vivo efficacy in mouse model.•Mechanism of action studies indicated thatpyridones are direct inhibitors of InhA.</description><subject>4-Hydroxy-2-pyridones</subject><subject>Animals</subject><subject>Antitubercular Agents - chemistry</subject><subject>Antitubercular Agents - metabolism</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Antituberculosis agents</subject><subject>Biological Availability</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Stability</subject><subject>Humans</subject><subject>Mice</subject><subject>Microbial Sensitivity Tests</subject><subject>Microsomes, Liver - chemistry</subject><subject>Microsomes, Liver - metabolism</subject><subject>Models, Molecular</subject><subject>Molecular Structure</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Phenotypic screen</subject><subject>Pyridones - chemistry</subject><subject>Pyridones - metabolism</subject><subject>Pyridones - pharmacology</subject><subject>Rats</subject><subject>Structure activity relations</subject><subject>Structure-Activity Relationship</subject><subject>Tuberculosis</subject><subject>Tuberculosis, Multidrug-Resistant - drug therapy</subject><subject>Tuberculosis, Multidrug-Resistant - microbiology</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVJaTZp_0EpPubizejTdg-FENokEOih7VlI8qirxWttJXmp_3292TTHnAZenneGeQj5SGFNgarr7Rq3O3SbNQMql2gN0L4hK9qotuZMijOyAsZ4LRkX5-Qi5y0ASAXwjpwzJYVQrFsR96OkyZUpYWVcCYdQ5irhYEqIY96Efa6ir0S9mfsU_841q_dzCn0cMX-ubqoxHnCo3GDyE2fGEspkMblpiDnkyvzGseT35K03Q8YPz_OS_Pr29eftff34_e7h9uaxdoK1pW4RBOXGU5DWdrZRIBS0PfDONVa1HZPMyF5J6z1yj154XDjWtbZTjbeWX5Kr0959in8mzEXvQnY4DGbEOGVNG84XXnbNgooT6lLMOaHX-xR2Js2agj7q1Vt90quPeo_ponepfXq-MNkd9i-l_z4X4MsJwOXPQ8Cksws4OuxDQld0H8PrF_4BHh2PHQ</recordid><startdate>20151201</startdate><enddate>20151201</enddate><creator>Ng, Pearly Shuyi</creator><creator>Manjunatha, Ujjini H.</creator><creator>Rao, Srinivasa P.S.</creator><creator>Camacho, Luis R.</creator><creator>Ma, Ngai Ling</creator><creator>Herve, Maxime</creator><creator>Noble, Christian G.</creator><creator>Goh, Anne</creator><creator>Peukert, Stefan</creator><creator>Diagana, Thierry T.</creator><creator>Smith, Paul W.</creator><creator>Kondreddi, Ravinder Reddy</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20151201</creationdate><title>Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents</title><author>Ng, Pearly Shuyi ; Manjunatha, Ujjini H. ; Rao, Srinivasa P.S. ; Camacho, Luis R. ; Ma, Ngai Ling ; Herve, Maxime ; Noble, Christian G. ; Goh, Anne ; Peukert, Stefan ; Diagana, Thierry T. ; Smith, Paul W. ; Kondreddi, Ravinder Reddy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-8e0413af105bb9b7604608d039c7b689252a5d65bffe3fef4febb9298b967fbb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>4-Hydroxy-2-pyridones</topic><topic>Animals</topic><topic>Antitubercular Agents - chemistry</topic><topic>Antitubercular Agents - metabolism</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Antituberculosis agents</topic><topic>Biological Availability</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Stability</topic><topic>Humans</topic><topic>Mice</topic><topic>Microbial Sensitivity Tests</topic><topic>Microsomes, Liver - chemistry</topic><topic>Microsomes, Liver - metabolism</topic><topic>Models, Molecular</topic><topic>Molecular Structure</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Phenotypic screen</topic><topic>Pyridones - chemistry</topic><topic>Pyridones - metabolism</topic><topic>Pyridones - pharmacology</topic><topic>Rats</topic><topic>Structure activity relations</topic><topic>Structure-Activity Relationship</topic><topic>Tuberculosis</topic><topic>Tuberculosis, Multidrug-Resistant - drug therapy</topic><topic>Tuberculosis, Multidrug-Resistant - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ng, Pearly Shuyi</creatorcontrib><creatorcontrib>Manjunatha, Ujjini H.</creatorcontrib><creatorcontrib>Rao, Srinivasa P.S.</creatorcontrib><creatorcontrib>Camacho, Luis R.</creatorcontrib><creatorcontrib>Ma, Ngai Ling</creatorcontrib><creatorcontrib>Herve, Maxime</creatorcontrib><creatorcontrib>Noble, Christian G.</creatorcontrib><creatorcontrib>Goh, Anne</creatorcontrib><creatorcontrib>Peukert, Stefan</creatorcontrib><creatorcontrib>Diagana, Thierry T.</creatorcontrib><creatorcontrib>Smith, Paul W.</creatorcontrib><creatorcontrib>Kondreddi, Ravinder Reddy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ng, Pearly Shuyi</au><au>Manjunatha, Ujjini H.</au><au>Rao, Srinivasa P.S.</au><au>Camacho, Luis R.</au><au>Ma, Ngai Ling</au><au>Herve, Maxime</au><au>Noble, Christian G.</au><au>Goh, Anne</au><au>Peukert, Stefan</au><au>Diagana, Thierry T.</au><au>Smith, Paul W.</au><au>Kondreddi, Ravinder Reddy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2015-12-01</date><risdate>2015</risdate><volume>106</volume><spage>144</spage><epage>156</epage><pages>144-156</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. Preliminary structure activity relationship on the isobutyl group with higher cycloalkyl groups at 6-position of pyridone ring has enabled us to significant improvement of potency against Mtb. The lead compound 30j, a dimethylcyclohexyl group on the 6-position of the pyridone, displayed desirable in vitro potency against both drug sensitive and multi-drug resistant TB clinical isolates. In addition, 30j displayed favorable oral pharmacokinetic properties and demonstrated in vivo efficacy in mouse model. These results emphasize the importance of 4-hydroxy-2-pyridones as a new chemotype and further optimization of properties to treat MDR-TB.
[Display omitted]
•Hit pyridone 1 inhibited growth of Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis.•SAR on 6-position of pyridone 1 significantly improved potency and lead compound 30j displayed 50 nM activity against Mtb.•Lead 30j showed favorable oral PK and demonstrated in vivo efficacy in mouse model.•Mechanism of action studies indicated thatpyridones are direct inhibitors of InhA.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>26544629</pmid><doi>10.1016/j.ejmech.2015.10.008</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2015-12, Vol.106, p.144-156 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_1733929597 |
source | ScienceDirect Freedom Collection |
subjects | 4-Hydroxy-2-pyridones Animals Antitubercular Agents - chemistry Antitubercular Agents - metabolism Antitubercular Agents - pharmacology Antituberculosis agents Biological Availability Dose-Response Relationship, Drug Drug Stability Humans Mice Microbial Sensitivity Tests Microsomes, Liver - chemistry Microsomes, Liver - metabolism Models, Molecular Molecular Structure Mycobacterium tuberculosis - drug effects Phenotypic screen Pyridones - chemistry Pyridones - metabolism Pyridones - pharmacology Rats Structure activity relations Structure-Activity Relationship Tuberculosis Tuberculosis, Multidrug-Resistant - drug therapy Tuberculosis, Multidrug-Resistant - microbiology |
title | Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A32%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structure%20activity%20relationships%20of%204-hydroxy-2-pyridones:%20A%20novel%20class%20of%20antituberculosis%20agents&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Ng,%20Pearly%20Shuyi&rft.date=2015-12-01&rft.volume=106&rft.spage=144&rft.epage=156&rft.pages=144-156&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2015.10.008&rft_dat=%3Cproquest_cross%3E1733929597%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c428t-8e0413af105bb9b7604608d039c7b689252a5d65bffe3fef4febb9298b967fbb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1733929597&rft_id=info:pmid/26544629&rfr_iscdi=true |